文献速递关节外科

慢性肾病是否影响初次髋膝关节置换术后的假体生存?

Does chronic kidney disease affect implant survival after primary hip and knee arthroplasty?
PubMed 文献 · Bone Joint J · 2021-01-01

这项单中心回顾性队列研究纳入18,979例连续髋膝关节置换术,中位随访5.6年,采用竞争风险分析发现,除正常肾功能膝关节置换患者全因翻修概率较高外,不同CKD分期在全因翻修或PJI相关翻修率上无重大差异。

要点

  • CKD分期与全因翻修或PJI翻修风险无强关联证据。
  • 膝关节置换中正常肾功能者全因翻修概率较高,可能为选择偏倚。
  • CKD 4-5期患者数量少,效应难以评估。

核心结论

  • 未发现CKD与全因翻修或PJI相关翻修风险增加有强关联的证据。
  • 膝关节置换中正常肾功能者全因翻修增多可能由选择偏倚解释。
  • CKD 4-5期效应因患者数量少难以评估。

研究设计与样本

  • 单中心高容量学术医院的回顾性队列研究,纳入18,979例连续髋膝关节置换术。
  • 中位随访5.6年(IQR 3.5至8.1),统计所有死亡和翻修。
  • 采用累积发生率函数(CIF)进行竞争风险分析,考虑糖尿病和BMI时使用分层CIF或Fine and Gray模型。

主要发现

  • 随访期间死亡2,111例(11.1%),翻修677例(3.6%),其中PJI翻修162例(0.9%)。
  • 髋关节置换8年内翻修率:CKD 1期3.5%,CKD 2期3.8%,CKD 3期4.2%,CKD 4-5期0%。
  • 膝关节置换8年内翻修率:正常肾功能4.7%,CKD 2期2.7%,CKD 3期2.4%,CKD 4-5期7%。
  • 除膝关节置换正常肾功能者全因翻修概率较高外,不同CKD分期全因翻修或PJI翻修率无重大差异。
  • 考虑糖尿病和BMI后结果不变。

关键数值与推荐

  • CKD分期依据原文定义,包括CKD 1期(正常肾功能,NKF)、CKD 2期、CKD 3期、CKD 4-5期。
  • 全因翻修率按髋、膝关节置换及CKD分期报告,随访8年。

临床怎么用

  • 对于髋膝关节置换患者,CKD分期不应单独作为翻修风险增高的强烈预测因素。
  • 膝关节置换正常肾功能患者全因翻修率较高,需注意选择偏倚可能。
  • CKD 4-5期患者证据有限,临床决策需个体化。

局限性

  • 单中心回顾性设计,可能存在选择偏倚。
  • CKD 4-5期患者数量少,效应难以评估。
  • 中位随访5.6年,长期结果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate whether chronic kidney disease (CKD) is associated with the risk of all-cause revision or revision due to a periprosthetic joint infection (PJI) after primary hip or knee arthroplasty. METHODS: This retrospective cohort study comprised 18,979 consecutive hip and knee arthroplasties from a single high-volume academic hospital. At a median of 5.6 years (interquartile range (IQR) 3.5 to 8.1), all deaths and revisions were counted. To overcome the competing risk of death, competing risk analysis using the cumulative incidence function (CIF) was applied to analyze the association between different stages of CKD and revisions. Confounding factors such as diabetes and BMI were considered using either a stratified CIF or the Fine and Gray model. RESULTS: There were 2,111 deaths (11.1%) and 677 revisions (3.6%) during the follow-up period. PJI was the reason for revision in 162 cases (0.9%). For hip arthroplasty, 3.5% of patients with CKD stage 1 (i.e. normal kidney function, NKF), 3.8% with CKD stage 2, 4.2% with CKD stage 3, and 0% with CKD stage 4 to 5 had undergone revision within eight years. For knee arthroplasty, 4.7% with NKF, 2.7% with CKD stage 2, 2.4% with CKD stage 3, and 7% of CKD stage 4 to 5 had had undergone revision. With the exception of knee arthroplasty patients in whom normal kidney function was associated with a greater probability of all-cause revision, there were no major differences in the rates of all-cause revisions or revisions due to PJIs between different CKD stages. The results remained unchanged when diabetes and BMI were considered. CONCLUSION: We found no strong evidence that CKD was associated with an increased risk of all-cause or PJI-related revision. Selection bias probably explains the increased amount of all-cause revision operations in knee arthroplasty patients with normal kidney function. The effect of stage 4 to 5 CKD was difficult to evaluate because of the small number of patients. Cite this article: Bone Joint J 2021;103-B(4):689-695.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Jämsä P, Reito A, Oksala N, et al. Does chronic kidney disease affect implant survival after primary hip and knee arthroplasty? Bone Joint J. 2021. PMID: 33789475. doi:10.1302/0301-620X.103B4.BJJ-2020-0715.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。